“LaunchTrends: Gilotrif Wave 3 (US)” is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched non-small-cell lung cancer (NSCLC) drug Gilotrif (Boehringer Ingelheim’s afatinib). In this report, we measure the impact of this new agent on the metastatic NSCLC therapy market based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. We focus on these physicians’ current awareness and perception of Gilotrif relative to other currently available therapies for metastatic NSCLC, their current and anticipated use of Gilotrif, and promotional activity of Gilotrif.
Questions Answered in This Report:
- What is the extent of physicians’ awareness of, and interest in, Gilotrif? How familiar are surveyed medical oncologists with Gilotrif’s prescribing information?
- What are the perceived clinical advantages and disadvantages of Gilotrif compared with other marketed agents used to treat NSCLC?
- To what extent is Gilotrif currently being used by surveyed medical oncologists? Where does it fit in the treatment algorithm among prescribers? When do nonprescribers expect to initiate use?
- What promotional messages is Boehringer Ingelheim using to promote Gilotrif?
Market covered: United States.
Primary research: Online survey of 82 medical oncologists; qualitative interviews with 10 respondents.
Indication coverage: Metastatic NSCLC.
Orestis Mavroudis-Chocholis, Ph.D.